

Rett Syndrome Research Trust Grant Funding Policy

The Rett Syndrome Research Trust (RSRT) is a charitable entity and is not committed to matching the indirect cost rates of the U.S. government or other entities. Total grant funding is inclusive of both direct costs and indirect costs.

Preclinical Research – RSRT research agreements with academic institutions provide an allowance for overhead and indirect costs equal to 10% of budgeted personnel and laboratory consumables costs incurred in connection with laboratory research projects. Costs associated with custom-made reagents, animals purchased from third parties, equipment, travel, and per diem expenses are not considered personnel or laboratory consumables costs for purposes of this overhead and indirect costs allowance.

Clinical Research – RSRT policy is that no indirect costs (0%) will be paid for clinical grants.

Budgets must be appropriate and justifiable for the work described. Funds awarded under these programs cannot be used for general equipment and travel costs except when clearly specified as essential to the execution of the proposed work. Each item and its cost must be clearly detailed in the budget and justified within the project description. In the event of collaboration between multiple institutions, indirect costs are only paid once, either to the principal investigator's (PI) institution as a percent of total direct costs, or in the case of multiple PIs, to each PI's institution as a percent of each institution's total direct costs.

For projects (e.g., clinical trials) where the true cost may exceed RSRT's budget limitations, RSRT is open to creative strategies for leveraging other funding sources applicants may have. For example, applicants may request RSRT funding to supplement an existing project in order to maximize data collected. Applicants should provide clear and detailed justification for how supplemental funding would enhance a project with respect to the ability to make critical decisions about study results.